齐拉西酮血浆浓度与其治疗精神分裂症临床效应的相关性分析

摘要

Objective To determine the relationship between plasma concentration of ziprasidone and its clinical efficacy in the treatment of schizophrenics. Methods Ziprasidone plasma concentration was determined with HPLC. Clinical efficacy was assessed with positive and negative syndrome scale (PANSS). SPSS17. 0 was used to explore the relationship between ziprasidone plasma concentration and clinical efficacy. Results There were no significant correlation between ziprasidone plasma concentration and the reducing rate of PANSS at the 2nd, 6th and 12th weekend of the treatment. Ziprasidone plasma concentration was significantly positively correlated with the reducing rate of SANS (P<0. 05). There was significant difference in reducing rate of SANS between the subgroup with ziprasidone plasma concentration above 88 |xg/L and those below 88 μg/L at the 12th weekend of the treatment (P <0. 05) . Conclusion The clinical efficacy of ziprasidone for the negative symptoms was correlated with its plasma concentration. The plasma concentration of ziprasidone should above 88 |xg/L.%目的 探讨齐拉西酮在中国精神分裂症患者体内的血药浓度与临床疗效的关系.方法 采用高效液相色谱法(HPLC)测定34例精神分裂症患者体内齐拉西酮的血浆药物浓度,疗效评定采用阳性与阴性症状量表(PANSS)评分,用SPSS17.0统计软件包对血药浓度与疗效评分进行统计分析.结果 治疗第2、6、12周末PANSS减分率与第2、6、12周末的齐拉西酮血浆浓度不相关,第6周末浓度与其SANS减分率呈正相关(P＜0.05).将12周末血药浓度分为小于88 μg/L组和大于88 μg/L组的疗效进行比较,阴性症状量表减分率两者的差异有统计学意义(P＜0.05).结论 结果支持齐拉西酮血浆浓度与其对精神分裂症阴性症状临床疗效相关.其血浆浓度＞88 μg/L时,疗效较好.